Evidence map›Paper›PMID 39703684›Full record

ArticleThe mental health clinician2024

Clinical pearls for the management of duloxetine patients with medical comorbidities.

Megan O'Connell, Amy VandenBerg

Abstract read
In one paragraph

Article in The mental health clinician, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Megan O'Connell(Corresponding author) Clinical Pharmacy Specialist, Psychiatry and Neurology, University of Michigan Health, Ann Arbor, Michigan, megan.oconnell77@gmail.com.ORCID https://orcid.org/0000-0003-1505-4178
Amy VandenBergClinical Pharmacy Specialist, Psychiatry and Neurology, University of Michigan Health, Ann Arbor, Michigan; Clinical Associate Professor of Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan.ORCID https://orcid.org/0000-0002-2294-2694

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effective use of duloxetine can be complicated by acute kidney injury, acute and/or chronic hepatic dysfunction, dysphagia, enteral nutrition, and common pharmacokinetic interactions. This article aimed to review the pharmacological properties of duloxetine pertinent to its use and to discuss the management of duloxetine in patients with common acute and chronic medical comorbidities. Management strategies based on clinical data and expert opinion are reviewed in 3 patient cases.

Indexed as

comorbiditiesdrug interactionsduloxetinehepatic functionnutrition statuspharmacokineticsrenal function

Identifiers

PMID39703684
PMCPMC11616965

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.